6CM
LRMR icon

683 Capital Management’s Larimar Therapeutics LRMR Stock Holding History

683 Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-70,000
Closed -$317K – 217
2023
Q1 		$317K Sell
70,000
-117,997
-63% -$616K 0.02% 144
2022
Q4 		$776K Sell
187,997
-166,931
-47% -$570K 0.07% 125
2022
Q3 		$1.14M Buy
354,928
+106,128
+43% +$266K 0.09% 117
2022
Q2 		$488K Sell
248,800
-1,200
-0.5% -$3.54K 0.03% 160
2022
Q1 		$1.01M Sell
250,000
-6,620
-3% -$43.3K 0.05% 159
2021
Q4 		$2.77M Hold
256,620
– – 0.1% 116
2021
Q3 		$2.96M Hold
256,620
– – 0.12% 100
2021
Q2 		$2.52M Buy
256,620
+36,484
+17% +$412K 0.09% 113
2021
Q1 		$3.22M Hold
220,136
– – 0.17% 84
2020
Q4 		$4.71M Hold
220,136
– – 0.22% 69
2020
Q3 		$3.34M Hold
220,136
– – 0.24% 69
2020
Q2 		$2.83M Buy
220,136
+939
+0.4% +$10.9K 0.23% 67
2020
Q1 		$2.02M Sell
219,197
-5,934
-3% -$78K 0.24% 69
2019
Q4 		$3M Buy
225,131
+30,847
+16% +$295K 0.34% 53
2019
Q3 		$1.72M Buy
194,284
+83,025
+75% +$910K 0.19% 67
2019
Q2 		$1.59M Hold
111,259
– – 0.14% 87
2019
Q1 		$3.66M Sell
111,259
-5,408
-5% -$277K 0.33% 61
2018
Q4 		$6.93M Buy
+116,667
New +$11.5M 0.42% 48
2018
Q3 		– Sell
-133,333
Closed -$16.4M – 171
2018
Q2 		$16.4M Buy
133,333
+25,000
+23% +$2.12M 1.11% 22
2018
Q1 		$9.69M Hold
108,333
– – 0.86% 36
2017
Q4 		$6.01M Hold
108,333
– – 0.51% 53
2017
Q3 		$4.58M Buy
108,333
+8,466
+8% +$352K 0.48% 54
2017
Q2 		$4.21M Buy
99,867
+46,243
+86% +$2.37M 0.62% 50
2017
Q1 		$3M Buy
53,624
+3,624
+7% +$180K 0.47% 54
2016
Q4 		$1.91M Buy
+50,000
New +$2.03M 0.14% 84

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

683 Capital Management's LRMR Position: Q2 2023 in Review

683 Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2023, closing a stake of 70,000 shares — an estimated $317K sold.

683 Capital Management first reported a position in LRMR in Q4 2016 and held it in 25 quarters. The position peaked at $16.4M in Q2 2018. 65 funds tracked by Wall St. Rank hold LRMR as of Q2 2023.

  • 683 Capital Management reported no remaining Larimar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 70,000 Larimar Therapeutics shares in Q2 2023, an estimated $317K.
  • 683 Capital Management first reported a position in Larimar Therapeutics in Q4 2016 and held it in 25 quarters.
  • 683 Capital Management's Larimar Therapeutics position peaked at $16.4M in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.